EMC Capital Management Has $106,000 Stock Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

EMC Capital Management raised its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 693.0% in the fourth quarter, HoldingsChannel reports. The fund owned 23,893 shares of the biotechnology company’s stock after purchasing an additional 20,880 shares during the quarter. EMC Capital Management’s holdings in Ironwood Pharmaceuticals were worth $106,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Dimensional Fund Advisors LP increased its stake in Ironwood Pharmaceuticals by 48.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 213,619 shares of the biotechnology company’s stock valued at $1,393,000 after purchasing an additional 69,848 shares in the last quarter. Hsbc Holdings PLC increased its position in shares of Ironwood Pharmaceuticals by 60.2% during the second quarter. Hsbc Holdings PLC now owns 25,923 shares of the biotechnology company’s stock worth $167,000 after acquiring an additional 9,740 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Ironwood Pharmaceuticals by 45.7% in the 2nd quarter. AQR Capital Management LLC now owns 684,578 shares of the biotechnology company’s stock worth $4,463,000 after acquiring an additional 214,836 shares during the last quarter. Algert Global LLC bought a new position in Ironwood Pharmaceuticals in the 2nd quarter valued at about $93,000. Finally, Handelsbanken Fonder AB boosted its stake in Ironwood Pharmaceuticals by 24.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 59,455 shares of the biotechnology company’s stock valued at $245,000 after purchasing an additional 11,600 shares during the last quarter.

Insider Transactions at Ironwood Pharmaceuticals

In other news, CFO Sravan Kumar Emany sold 11,001 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $4.08, for a total transaction of $44,884.08. Following the completion of the transaction, the chief financial officer now owns 309,572 shares in the company, valued at approximately $1,263,053.76. This represents a 3.43 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on IRWD shares. StockNews.com lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Craig Hallum cut their price objective on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. Finally, JMP Securities lowered their target price on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a report on Thursday. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.67.

Ironwood Pharmaceuticals Stock Down 38.2 %

Shares of Ironwood Pharmaceuticals stock opened at $2.30 on Friday. Ironwood Pharmaceuticals, Inc. has a 1 year low of $2.25 and a 1 year high of $15.70. The stock has a fifty day moving average price of $3.90 and a 200-day moving average price of $4.50.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). The company had revenue of $91.60 million for the quarter, compared to analysts’ expectations of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business’s quarterly revenue was down 19.4% on a year-over-year basis. During the same quarter last year, the business posted $0.12 EPS. As a group, equities research analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.08 EPS for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.